These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24341382)

  • 1. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
    Leaker BR; Barnes PJ; O'Connor B
    Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor.
    Virtala R; Ekman AK; Jansson L; Westin U; Cardell LO
    Clin Exp Allergy; 2012 Apr; 42(4):590-6. PubMed ID: 22192144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
    Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
    Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
    Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers.
    Hernandez ML; Mills K; Almond M; Todoric K; Aleman MM; Zhang H; Zhou H; Peden DB
    J Allergy Clin Immunol; 2015 Feb; 135(2):379-85. PubMed ID: 25195169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
    De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
    Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
    Nair P; Gaga M; Zervas E; Alagha K; Hargreave FE; O'Byrne PM; Stryszak P; Gann L; Sadeh J; Chanez P;
    Clin Exp Allergy; 2012 Jul; 42(7):1097-103. PubMed ID: 22702508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
    Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
    Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial.
    Simpson JL; Powell H; Baines KJ; Milne D; Coxson HO; Hansbro PM; Gibson PG
    PLoS One; 2014; 9(8):e105609. PubMed ID: 25148049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis.
    Malla SR; Kärrman Mårdh C; Günther A; Mahajan UM; Sendler M; D'Haese J; Weiss FU; Lerch MM; Hansen MB; Mayerle J
    Pancreatology; 2016; 16(5):761-9. PubMed ID: 27450968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
    Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
    Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects.
    Nightingale JA; Rogers DF; Hart LA; Kharitonov SA; Chung KF; Barnes PJ
    Thorax; 1998 Jul; 53(7):563-71. PubMed ID: 9797755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
    Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
    J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M; Singh D
    J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
    Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
    J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development.
    Janssen O; Schaumann F; Holz O; Lavae-Mokhtari B; Welker L; Winkler C; Biller H; Krug N; Hohlfeld JM
    BMC Pulm Med; 2013 Mar; 13():19. PubMed ID: 23537365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.